Is IVA a good stock to buy? We came across a bullish thesis on Inventiva S.A. on BioEquity Watch’s Substack. Since the thesis was published on July 31st, IVA shares have pulled back as investors weigh the upcoming Phase 3 NATiV3 results and the company’s financing needs, but the trial results could still shape the drug’s future. In this article, we will summarize the bulls’ thesis on IVA. Inventiva S.A.’s share was trading at $3.6850 as of October 27th 2026.
This isn’t the first...
